Celularity Inc. Warrant (CELUW) Stock Price
CELUWStock
$0.00
Market Cap—
P/E—
PEG Ratio—
Div yield—
Beta0.81
CELUW Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-99.14%
Price vs S&P 500 (4W)-66.20%
VGM Score26.07
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CELUWCelularity Inc. Warrant | — | — | D | $0.00 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Celularity Inc. Warrant
Celularity is a clinical-stage biotechnology company developing off-the-shelf, placental-derived cell therapies for cancer, immunologic, infectious, and degenerative diseases. Its pipeline includes natural killer cells, CAR-T cells, and mesenchymal stromal cells, both engineered and unmodified. The company operates through three segments—Cell Therapy, Degenerative Disease, and bio-banking—with bio-banking currently generating the majority of its revenue.